SABCS 2022 | Phase I/II study of pembrolizumab + binimetinib in unresectable locally advanced or metastatic TNBC

Saranya Chumsri, MD, Mayo Clinic, Jacksonville, FL, provides an overview of the Phase I/II trial (NCT03106415) of the MEK inhibitor binimetinib in combination with pembrolizumab in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Previous in vivo studies have shown the inhibition of the MAPK pathway with a MEK inhibitor is synergistic with immune checkpoint inhibitors. Pembrolizumab in combination with binimetinib at 30 mg twice daily was observed to be safe with manageable toxicities. The primary outcomes were maximum tolerated dose (MTD) of pembrolizumab in combination with binimetinib and objective-response rate (ORR). Secondary outcomes include progression-free survival (PFS) and overall-survival (OS). ORR was approximately 24.9% and the clinical benefit rate (CBR) was 35.29%. ORR in patients without liver metastases was 55.56% and CBR was 66.67%. Overall, promising activity with durable responses was observed with binimetinib in combination with pembrolizumab without chemotherapy, particularly in patients without liver metastases. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.